Compare NPV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPV | MGNX |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 256.8M |
| IPO Year | 1995 | 2013 |
| Metric | NPV | MGNX |
|---|---|---|
| Price | $10.59 | $4.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 79.0K | ★ 641.7K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.07 | $1.30 |
| 52 Week High | $11.81 | $5.08 |
| Indicator | NPV | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 52.68 |
| Support Level | $10.07 | $3.81 |
| Resistance Level | $11.32 | $4.38 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 64.65 | 78.06 |
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.